


**AMENDMENTS TO THE CLAIMS**

Claims 1-23 (CANCELLED)

24. (New) A 1,5-disubstituted benzimidazol-2-one derivative having the general Formula I



wherein

R' represents hydrogen or alkyl;

R'' represents halogen or trihalogenmethyl; and

Hlg represents halogen;

provided, however, that

if Hlg is F, then R'' is not Cl.

25. (New) The benzimidazol-2-one derivative of claim 24, wherein

Hlg represents Cl or Br.

26. (New) The benzimidazol-2-one derivative of claim 24, wherein

R' represents hydrogen or methyl.

27. (New) The benzimidazol-2-one derivative of claim 24, wherein

R'' represents halogen or CF<sub>3</sub>.

28. (New) The benzimidazol-2-one derivative of claim 27, wherein

R''' represents Cl or CF<sub>3</sub>.

29. (New) The benzimidazol-2-one derivative of claim 24, which is

1-(5-chloro-2-hydroxyphenyl)-5-chloro-1,3-dihydro-2H-benzimidazo-2-one; or

1-(5-trifluoromethyl-2-hydroxyphenyl)-5-chloro-1,3-dihydro-2H-benzimidazo-2-one;

or a pharmaceutically-acceptable salt thereof.

30. (New) A pharmaceutical composition comprising a therapeutically effective amount of the benzimidazol-2-one derivative of claim 24, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.

31. (New) The pharmaceutical composition of claim 30, which composition comprises a further therapeutic agent.

32. (New) A method of treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of BK<sub>Ca</sub> channels, which method comprises the step of administering to such a living animal body in need thereof, a therapeutically effective amount of a benzimidazol-2-one derivative according to claim 24, or a pharmaceutically-acceptable salt thereof.

33. (New) The method according to claim 32, wherein the disease, disorder or condition is an obstructive or inflammatory airway disease.

34. (New) The method according to claim 33, wherein the obstructive or inflammatory airway disease is an airway hyperreactivity, a pneumoconiosis such as aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis and byssinosis, a chronic obstructive pulmonary disease (COPD), bronchitis, exacerbation of airways hyperreactivity or cystic fibrosis.

35. (New) The method according to claim 32, wherein the disease, disorder or condition is a cardiovascular disease, in particular atherosclerosis, ischemia/reperfusion, hypertension, restenosis, arterial inflammation, myocardial ischaemia and ischaemic heart disease.

36. (New) The method of a benzimidazol-2-one derivative according to claim 24, or a pharmaceutically-acceptable addition salt thereof, for the manufacture of a medicament useful for increasing the blood-brain barrier permeability.

37. (New) The method according to claim 36, for the manufacture of a medicament useful for co-administration of a therapeutic agent.

38. (New) The method according to claim 37, wherein the therapeutic agent is an antineoplastic agent, a chemotherapeutic agent, a cytotoxic agent, a DNA expression vector, a protein, an oligonucleotide, a nucleotide analog, an antimicrobial agent, an interferon, a cytokine, a cytokine agonist, a cytokine antagonist, an immunotoxin, an immunosuppressant, a boron compound, a monoclonal antibody, an adrenergic agent, an anticonvulsant, an ischemia-protective agent, an anti-trauma agent, an anticancer chemotherapeutic agent or a diagnostic agent.

39. (New) The method according to claim 38, wherein the DNA expression vector is a viral vector, preferably an adenovirus-derived vector or herpes simplex virus-derived vector.

40. (New) The method according to claim 38, wherein the diagnostic agent is an imaging or contrast agent, preferably a radioactively labelled substance, a gallium-labelled substance, or a contrast agent selected from the group consisting of ferrous magnetic, fluorescent, luminescent, and iodinated contrast agents.

41. (New) A kit-of-parts useful for enhancing the delivery of a medicament to the brain, which kit comprises:

A benzimidazol-2-one derivative of claim 24;

A therapeutic agent; and

Instructions for using the 1,5-disubstituted benzimidazol-2-one derivative for enhancing delivery of the therapeutic agent to the brain.